Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
AgomAb Therapeutics NV ADR +5.07% Post
AgomAb Therapeutics NV ADR AGMB | 11.20 11.20 | +5.07% 0.00% Post |
Feb 6 (Reuters) - Shares of Agomab Therapeutics AGMB.O fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million.
